GlassScriptPhysician profile
Christopher M Hinson
NPI 1952780066
$5,603.21
in general payments reported to CMS, 2019-2025
28 companies · $372 in 2025
The $372 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $396 · 2020: $345 · 2021: $1,000 · 2022: $2,587 · 2023: $392 · 2024: $510 · 2025: $372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,274.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,778.23 | 2021-2025 | Hawkone |
| Inari Medical, INC. | $574.10 | 2022-2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $506.36 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $469.39 | 2019-2023 | Brilinta |
| Pfizer INC. | $327.83 | 2020-2022 | |
| Abiomed | $321.08 | 2023-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $294.16 | 2020-2025 | |
| Irhythm Technologies, INC. | $187.86 | 2021-2023 | Zio Xt Patch |
| Edwards Lifesciences Corporation | $158.11 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $153.56 | 2021-2025 | Eliquis, Camzyos |
| Lantheus Medical Imaging, INC. | $131.38 | 2019 | |
| Shockwave Medical, INC | $108.47 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Janssen Pharmaceuticals, INC | $102.22 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $95.15 | 2020 | |
| Impulse Dynamics (USA) INC. | $82.48 | 2022-2023 | Optimizer |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akcea Therapeutics, INC. | $43.85 | 2019-2020 | |
| Penumbra, INC. | $42.00 | 2025 | Indigo System |
| Actelion Pharmaceuticals US, INC. | $38.76 | 2022-2023 | Uptravi |
| Amgen INC. | $25.54 | 2022 | |
| Abbott Laboratories | $24.42 | 2025 | Cardiomems |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.45 | 2021 | |
| Astellas Pharma US INC | $20.09 | 2019 | |
| Biosense Webster, INC. | $19.21 | 2025 | Carto 3 |
| Boston Scientific Corporation | $17.07 | 2022 | |
| Stryker Corporation | $16.09 | 2025 | Artix Mt |
| Cardiovascular Systems INC. | $15.08 | 2021 | |
| Medtronic Vascular, INC. | $13.70 | 2020 | |
| Merck Sharp & Dohme LLC | $13.57 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Hinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.